Nature Publishes Promising Results on Treatment of First Patient in bluebird bio’s (Columbia) Phase 1/2 Beta-Thalassemia Study (9/15/2010)

bluebird bio is a Columbia spinoff developing innovative gene therapies for severe genetic disorders.

bluebird bio (formerly Genetix Pharmaceuticals Inc.) an emerging leader in the development of innovative gene therapies for severe genetic disorders, today announced publication in the journal Nature of its promising Phase 1/2 data highlighting positive results of LentiGlobinTM gene therapy treatment in a young adult with severe beta- thalassemia, a blood disorder that is one of the most frequent inherited diseases. [read more]

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s


%d bloggers like this: